JPWO2020102591A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020102591A5 JPWO2020102591A5 JP2021526461A JP2021526461A JPWO2020102591A5 JP WO2020102591 A5 JPWO2020102591 A5 JP WO2020102591A5 JP 2021526461 A JP2021526461 A JP 2021526461A JP 2021526461 A JP2021526461 A JP 2021526461A JP WO2020102591 A5 JPWO2020102591 A5 JP WO2020102591A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal
- antibody
- amino acid
- presented
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 38
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 38
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 8
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 8
- 102000000588 Interleukin-2 Human genes 0.000 claims 6
- 108010002350 Interleukin-2 Proteins 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 229960004669 basiliximab Drugs 0.000 claims 2
- 229960002806 daclizumab Drugs 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 238000005829 trimerization reaction Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024158123A JP2024175003A (ja) | 2018-11-14 | 2024-09-12 | Ｃｄ２５抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767405P | 2018-11-14 | 2018-11-14 | |
| US62/767,405 | 2018-11-14 | ||
| PCT/US2019/061552 WO2020102591A1 (en) | 2018-11-14 | 2019-11-14 | Cd25 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024158123A Division JP2024175003A (ja) | 2018-11-14 | 2024-09-12 | Ｃｄ２５抗体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022507487A JP2022507487A (ja) | 2022-01-18 |
| JPWO2020102591A5 true JPWO2020102591A5 (https=) | 2023-06-14 |
| JP2022507487A5 JP2022507487A5 (https=) | 2023-06-14 |
| JP7619941B2 JP7619941B2 (ja) | 2025-01-22 |
Family
ID=70730731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526461A Active JP7619941B2 (ja) | 2018-11-14 | 2019-11-14 | Ｃｄ２５抗体 |
| JP2024158123A Pending JP2024175003A (ja) | 2018-11-14 | 2024-09-12 | Ｃｄ２５抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024158123A Pending JP2024175003A (ja) | 2018-11-14 | 2024-09-12 | Ｃｄ２５抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12215163B2 (https=) |
| EP (1) | EP3880227A4 (https=) |
| JP (2) | JP7619941B2 (https=) |
| CN (1) | CN113677359A (https=) |
| CA (1) | CA3120096A1 (https=) |
| WO (1) | WO2020102591A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109053882B (zh) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | 一种ns1蛋白的结合蛋白以及应用 |
| EP3880698A4 (en) | 2018-11-14 | 2022-11-30 | RubrYc Therapeutics, Inc. | MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF |
| MX2022001065A (es) * | 2019-07-30 | 2022-02-14 | Shanghai Hansoh Biomedical Co Ltd | Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo. |
| US20230049732A1 (en) * | 2019-12-30 | 2023-02-16 | University Of Louisville Research Foundation, Inc. | Virus-like particle binding agents, related compositions, and related methods |
| CA3201423A1 (en) | 2020-11-13 | 2022-05-19 | Ibio, Inc. | Cd25 antibodies |
| WO2022235295A1 (en) * | 2021-05-07 | 2022-11-10 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
| JP2024532790A (ja) * | 2021-08-09 | 2024-09-10 | 南京▲諾▼艾新生物技▲術▼有限公司 | 組換え抗ヒトｃｄ２５抗体及びその使用 |
| CA3228786A1 (en) * | 2021-08-25 | 2023-03-02 | Ibio, Inc. | Anti-cd25 antibody |
| CN118829654A (zh) * | 2021-12-29 | 2024-10-22 | 舒泰神(加州)生物科技有限公司 | 特异性识别C5aR1的抗体及其应用 |
| US20250154268A1 (en) * | 2022-01-17 | 2025-05-15 | Nona Biosciences (Suzhou) Co., Ltd. | Antibody targeting cd25, and preparation method therefor and use thereof |
| CN119451978A (zh) | 2022-07-01 | 2025-02-14 | 神经基因治疗公司 | Neo-2/15变体及其用于优先刺激T调节细胞的用途 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| TW202509067A (zh) * | 2023-04-11 | 2025-03-01 | 大陸商蘇州創勝醫藥集團有限公司 | 抗ｃｄ２５抗體及其用途 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN117050165B (zh) * | 2023-08-14 | 2025-03-25 | 三优生物医药(上海)有限公司 | 一种靶向猴痘病毒的抗体、其抗原结合片段及其用途 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN119331099B (zh) * | 2024-11-06 | 2025-12-16 | 郑州伊美诺生物技术有限公司 | 抗嗜酸性粒细胞过氧化物酶的单克隆抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7438907B2 (en) * | 2002-11-15 | 2008-10-21 | Genmab A/S | Human monoclonal antibodies against CD25 |
| CN107129524B (zh) * | 2007-09-25 | 2023-11-21 | 田园温室气体研究有限公司 | 用于抑制微生物细胞的疫苗和疫苗组分 |
| WO2011051327A2 (en) * | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| WO2014028776A1 (en) * | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| EP2970486B1 (en) * | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| WO2016179212A1 (en) * | 2015-05-05 | 2016-11-10 | Albert Einstein College Of Medicine, Inc. | Antibody therapeutics against filovirus infections and uses thereof |
| WO2018089829A1 (en) | 2016-11-10 | 2018-05-17 | Fortis Therapeutics, Inc. | Cd46-specific effector cells and uses thereof |
| US11879014B2 (en) * | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| CN110856446A (zh) | 2017-04-18 | 2020-02-28 | 阿法姆海外股份有限公司 | 抗pd-l1抗体及其用途 |
| EP3880698A4 (en) | 2018-11-14 | 2022-11-30 | RubrYc Therapeutics, Inc. | MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF |
-
2019
- 2019-11-14 CA CA3120096A patent/CA3120096A1/en active Pending
- 2019-11-14 CN CN201980088154.1A patent/CN113677359A/zh active Pending
- 2019-11-14 JP JP2021526461A patent/JP7619941B2/ja active Active
- 2019-11-14 EP EP19883467.3A patent/EP3880227A4/en active Pending
- 2019-11-14 WO PCT/US2019/061552 patent/WO2020102591A1/en not_active Ceased
-
2021
- 2021-05-13 US US17/320,125 patent/US12215163B2/en active Active
-
2024
- 2024-09-12 JP JP2024158123A patent/JP2024175003A/ja active Pending
- 2024-12-04 US US18/968,640 patent/US20250122301A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024175003A5 (https=) | ||
| JPWO2020102591A5 (https=) | ||
| JP2021534096A5 (https=) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2020510422A5 (https=) | ||
| JP2020525032A5 (https=) | ||
| JP2017520575A5 (https=) | ||
| JP2019536430A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| JP2018531219A (ja) | Ｐｄ−ｌ１抗体 | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| JP2018520657A5 (https=) | ||
| JP2016505556A5 (https=) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2018510617A5 (https=) | ||
| JPWO2022046944A5 (https=) | ||
| JP2020500834A5 (https=) | ||
| JP2020502233A5 (https=) | ||
| JP2024024114A5 (https=) | ||
| JP2021522347A5 (https=) | ||
| US20240101675A1 (en) | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof | |
| JP2021531255A5 (https=) | ||
| JP2020533965A5 (https=) | ||
| JP2020531003A5 (https=) | ||
| CN114829405A (zh) | 抗bcma/抗4-1bb双特异性抗体及其用途 |